Altrip Tablet - (6.25mg)contains Almotriptan Malateequivalent to 6.25 mg of Almotriptan. 
It is manufactured by NIPRO JMI Pharma Ltd.in Bangladesh.

Indications:

Altrip is used to treat the acute headache phase of migraine attacks with or without aura in adults and adolescents aged 12 to 17 years.

Pharmacology:

Almotriptan is a selective and potent serotonin (5-hydroxytryptamine 1B/1D) agonist. It binds to specific serotonin receptors on meningeal arteries, inhibiting the release of vasoactive peptides and causing constriction of these arteries. It has a limited effect on arteries supplying blood to the brain and little effect on cardiac and pulmonary vessels.

Dosageand Administration:

• Adults and Adolescents (12 to 17 years): The recommended dose is 6.25 mg to 12.5 mg. The 12.5 mg dose tends to be more effective in adults. If the headache is relieved but returns, the dose may be repeated after 2 hours. The maximum daily dose should not exceed 25 mg. 
• The safety of treating an average of more than four migraines in a30-day period has not been established. 
• Hepatic Impairment:The recommended starting doseis 6.25 mg. The maximum daily dose should not exceed 12.5 mg over 24 hours.
• Renal Impairment: The recommended starting dose in patients with severe renal impairment is 6.25 mg. The maximum daily dose should not exceed 12.5 mg over 24 hours. 
• Altrip can be taken with or without food.  

Side Effects:

Serious cardiac reactions, including myocardial infarction, have occurred following the use of Almotriptan malate tablets. These reactions are extremely rare and most have been reported in patients with risk factors for coronary artery disease (CAD). Common side effects may include somnolence (sleepiness), dizziness, nausea, vomiting, dry mouth, and headache.

Precautions:

Altrip should not be used in patients with a history, symptoms, or signs of ischemic heart disease (myocardial infarction, angina pectoris, documented silent ischemia, Prinzmetal's angina) or severe hypertension and uncontrolled mild or moderate hypertension. Concomitant administration with ergotamine, ergotamine derivatives (including methysergide), and other 5-HT1B/1D agonists is contraindicated.1314 Caution should be exercised in patients with hypersensitivity to the active substance or any excipients, severe hepatic impairment, a previous cerebrovascular accident (CVA) or transient ischemic attack (TIA), and peripheral vascular disease.

Important Note: This information is for general knowledge and informational purposes only and does not substitute professional medical advice. Always consult your doctor or pharmacist for specific instructions and guidance regarding your medication. They can assess your individual medical condition and provide the most appropriate advice.